A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000007120
- Lead Sponsor
- Kanagawa Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Not provided
1)pulmonary fibrosis or interstitial pneumonitis evident 2)Massive pleural effusion, pericardial effusion,and abdominal effusion 3)Simultaneous or metachronous double cancers 4)serious complications below a)myocardial infarction within 6 months b)Uncontrolled diabetes or hypertension c)Current severe infection, or suspicious of severe infection d)History of serious drug allergic reaction e)Massive effusion or edema f)Patients whose participation in the trial is judged to be inappropriate by the attending doctor 5)Symptomatic brain metastasis 6)now pregnant or lactation 7)History of radiation therapy or operation for lung cancer within 28 days at the time of entry. 8)History of unapproved drugs within 28 days at the time of entry. 9)Participation in this study before 10)History of serious allergic reaction with S-1 11)Being treated with other pyrimidine fluoride antineoplastic agents. 12)Being treated with flucytosine. 13)Wattery diarrhea 14)lactose intolerance 15)difficult to perform or continue of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method RD : Recommended Dose
- Secondary Outcome Measures
Name Time Method Safety,Efficacy,Immunological response,QO